Milestones in Huntington disease
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
There have been extraordinary advances in our knowledge of the underlying gene, the protein it encodes, various models of disease, and potential targets for effective therapies for Huntington disease. Huntington disease research has increased exponentially in the past 25 years, and we now understand many of the molecular mechanisms underlying the disease. Still, more work needs to be done before we have a full understanding of the pathophysiology of the disease. Clinical research on biomarkers and clinical trials on potential neuroprotective agents are underway. Here we review our progress in these areas over the last 25 years and speculate on what the next 25 years may hold. © 2011 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228 · cited 1×
“Potential disease-modifying treatments might best be initiated prior to the onset of HD, when pathogenic mechanisms are potentially more reversible.(81) A randomized, controlled study (PREQUEL) has been designed to examine the safety, tolerability, and dosage of coenzyme Q10 in unaffected (premanifest) individuals who…”
BackgroundTabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70170-x · Cited by 984 · cited 1×
“Striatal atrophy as well as white matter loss as measured by standardized MRI volumetric analysis can be detected at least 15 years prior to predicted onset and progresses steadily during the prodromal premanifest period.(19,20) In addition, cortical thinning develops during the prodromal period in parallel with the e…”
BackgroundEffects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Weydt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., Gilbert, M. L., Morton, G. J., Bammler, T. K., Strand, A. D., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.004 · Cited by 562
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522
Cha, J.-H. J., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6480 · Cited by 504
Self-citationTetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
Shults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194318.74946.b6 · Cited by 313 · cited 1×
“The white matter including the corpus callosum is atrophied.(26) The cortical atrophy progresses from the motorsensory cortex to the occipital, parietal, and limbic cortices.”
BackgroundA randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease
The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312 · cited 2×
“In contrast, individuals treated with coenzyme Q10 showed about a 13% slowing in functional decline (P ¼ .15) as well as a benefit on cognitive measures compared with individuals not receiving coenzyme Q10.”
Background
Cited by
The incidence and prevalence of Huntington's disease: A systematic review and meta‐analysis
Pringsheim, T., Wiltshire, K., Day, L., Dykeman, J., Steeves, T., & Jette, N. (2012) · Movement Disorders · doi:10.1002/mds.25075 · Cited by 587
Rüb, U., Schöls, L., Paulson, H., Auburger, G., Kermer, P., Jen, J. C., Seidel, K., Korf, H.-W., & Deller, T. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.01.001 · Cited by 346
Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease
Oster, E., Shoulson, I., & Dorsey, E. R. (2013) · American Economic Review · doi:10.1257/aer.103.2.804 · Cited by 290
Self-citationThe pig as an animal model for human pathologies: A proteomics perspective
Bassols, A., Costa, C., Eckersall, P. D., Osada, J., Sabrià, J., & Tibau, J. (2014) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300099 · Cited by 254
Rüb, U., Seidel, K., Heinsen, H., Vonsattel, J. P., den Dunnen, W. F., & Korf, H. W. (2016) · Brain Pathology · doi:10.1111/bpa.12426 · Cited by 206
“Despite progress, understanding of the molecular biological basis and exact pathophysiological mechanisms of the formation of the various forms of aggregations in diseased nerve cells, as well as their relevance to the demise of nerve cells that takes place in HD, remain only incompletely understood (3, 5, 9, 20, 36,…”
Background
Metadata
- Authors
- Shoulson, I., & Young, A. B.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2011-05
- Volume
- 26
- Issue
- 6
- Pages
- 1127-1133
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2160615365
- Cited by
- 70
- References
- 11
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Milestones in Huntington disease. https://app.cochat.ai/papers/10.1002/mds.23685
- The paper
- Shoulson, I., & Young, A. B. (2011). Milestones in Huntington disease. Movement Disorders. https://doi.org/10.1002/mds.23685
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.